Tag: JAK2

Ruxolitinib (INCB018424) is an Orally Active JAK1 and JAK2 Inhibitor

The myeloproliferative neoplasms (MPNs) are a group of related clonal diseases probably arising from hematopoietic progenitor or stem cells. Patients with MPNs have an increased risk of thrombotic and bleeding complications and disease progression to acute myeloid leukemia. JAK2 is a member of the JAK family of cytoplasmic tyrosine...

Barasertib, a Pro-Drug of Barasertib-hQPA, is a Highly Selective Aurora B Inhibitor

Aurora kinases play an important role during mitosis for chromosome alignment, segregation, and cytokinesis. Selective Targeting of Aurora B kinase may be a promising therapeutic approach for the treatment of a range of malignancies. In this study, researchers explored the effect of Barasertib. In particular, Barasertib is a highly...

NSC 33994 is a Selective JAK2 Inhibitor

Janus kinases (JAK) play a crucial role in cytokine-mediated signal transduction. Activated JAKs tyrosine autophosphorylate and phosphorylate specific tyrosine residues on the C-terminal end. This results in the recruitment and activation of the STAT proteins. Activated STATs subsequently translocate into the nucleus where they alter specific gene transcription patterns....

G5-7, an Orally Active JAK2 Inhibitor, Induces Cell Cycle Arrest and Apoptosis

JAK2 and STAT3 have been extensively implicated in the development and progression of numerous cancers. STAT3 be also activated by EGFR, JAK2, and other TYKs activated by EGF, LIF, and other cytokines. STAT3 constitutively activats in 60% of primary malignant gliomas, and the extent of activation correlates with glioma...

SC99 is an Orally Active and Selective STAT3 Inhibitor

STAT3 is a member of the STAT protein family. STAT3 mediates the expression of a variety of genes in response to cell stimulation. So it plays a key role in many cell processes, such as cell growth and apoptosis. Specifically, the oncogenic STAT3 signaling pathway is becoming a promising...